An Open-label, Multicenter Safety and Tolerability Study of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Pediatric Subjects Aged < 4 Years With Neurologic Manifestations of Niemann-Pick Type C (NPC) Disease
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 13 May 2019
Price : $35 *
At a glance
- Drugs Adrabetadex (Primary)
- Indications Niemann-Pick disease type C
- Focus Adverse reactions
- Sponsors Vtesse
- 07 May 2019 Planned initiation date changed from 29 Mar 2019 to 1 Nov 2019.
- 04 Dec 2018 Planned initiation date changed from 30 Oct 2018 to 29 Mar 2019.
- 01 Oct 2018 New trial record